{
    "clinical_study": {
        "@rank": "68877", 
        "arm_group": [
            {
                "arm_group_label": "Teduglutide treated", 
                "description": "- SBS patients who have been treated with teduglutide"
            }, 
            {
                "arm_group_label": "Non-teduglutide treated", 
                "description": "- SBS patients who have not been treated with teduglutide"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a global prospective, observational, multi-center registry to evaluate the long-term\n      safety profile for patients with short bowel syndrome (SBS) who are treated with teduglutide\n      in a routine clinical setting. The registry will also evaluate the long-term clinical\n      outcomes in patients with SBS. SBS patients treated and not treated with teduglutide will be\n      enrolled."
        }, 
        "brief_title": "A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome", 
        "completion_date": {
            "#text": "December 2029", 
            "@type": "Anticipated"
        }, 
        "condition": "Short Bowel Syndrome", 
        "condition_browse": {
            "mesh_term": "Short Bowel Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male and female patients, of any age, with a diagnosis of SBS\n\n          2. Signed informed consent and medical records release by the patient or a  legally\n             acceptable representative\n\n        Exclusion Criteria:\n\n        None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "This registry is to enroll both male and female patients, of any age, with a diagnosis of\n        SBS."
            }
        }, 
        "enrollment": {
            "#text": "1310", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01990040", 
            "org_study_id": "TED-R13-002"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Short Bowel Syndrome", 
            "SBS", 
            "teduglutide", 
            "Gattex"
        ], 
        "lastchanged_date": "April 1, 2014", 
        "number_of_groups": "2", 
        "official_title": "A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2028", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Occurrence of colorectal cancer in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting", 
            "safety_issue": "Yes", 
            "time_frame": "At least 10 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01990040"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Occurrence of other malignancy in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting", 
                "safety_issue": "Yes", 
                "time_frame": "At least 10 years"
            }, 
            {
                "measure": "Actual volume change in parenteral support in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting", 
                "safety_issue": "No", 
                "time_frame": "At least 10 years"
            }, 
            {
                "measure": "Occurrence of benign neoplasia of the gastrointestinal tract, hepatobiliary system, and pancreas in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting", 
                "safety_issue": "Yes", 
                "time_frame": "10 years"
            }, 
            {
                "measure": "Occurrence of colorectal polyps in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting", 
                "safety_issue": "Yes", 
                "time_frame": "10 years"
            }, 
            {
                "measure": "Occurrence of intestinal obstruction in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting", 
                "safety_issue": "Yes", 
                "time_frame": "10 years"
            }, 
            {
                "measure": "Occurrence of pancreatic and biliary disease in patients with short bowel syndrome who who are treated with teduglutide in a routine clinical setting", 
                "safety_issue": "Yes", 
                "time_frame": "10 years"
            }, 
            {
                "measure": "Occurrence of heart failure and other manifestations of volume overload  in patients with short bowel syndrome who who are treated with teduglutide in a routine clinical setting", 
                "safety_issue": "Yes", 
                "time_frame": "10 years"
            }, 
            {
                "measure": "Occurrence of allergic/hypersensitivity reaction to teduglutide in patients with short bowel syndrome who who are treated with teduglutide in a routine clinical setting", 
                "safety_issue": "Yes", 
                "time_frame": "10 years"
            }, 
            {
                "measure": "Percentage volume change in parenteral support in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting", 
                "safety_issue": "No", 
                "time_frame": "10 years"
            }, 
            {
                "measure": "Occurrence of other long-term safety outcomes in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting", 
                "safety_issue": "Yes", 
                "time_frame": "10 years"
            }
        ], 
        "source": "NPS Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "NPS Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "10 Years", 
        "verification_date": "April 2014"
    }
}